Aethlon Medical (NASDAQ:AEMD) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Aethlon Medical (NASDAQ:AEMD) in a research report report published on Friday,Benzinga reports. The firm currently has a $7.00 price target on the medical equipment provider’s stock.

Separately, StockNews.com initiated coverage on Aethlon Medical in a report on Friday, November 8th. They issued a “sell” rating on the stock.

Aethlon Medical Price Performance

Shares of NASDAQ:AEMD remained flat at $0.40 during mid-day trading on Friday. 555,187 shares of the stock traded hands, compared to its average volume of 1,853,455. Aethlon Medical has a 12 month low of $0.24 and a 12 month high of $2.35. The firm has a market capitalization of $5.57 million, a P/E ratio of -0.14 and a beta of 1.74. The company has a 50 day moving average of $0.40 and a two-hundred day moving average of $0.49.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings data on Wednesday, August 14th. The medical equipment provider reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.10. During the same quarter in the prior year, the business earned ($1.30) earnings per share. On average, equities research analysts predict that Aethlon Medical will post -1.1 earnings per share for the current year.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.